Arctic Therapeutics
Clinical trials sponsored by Arctic Therapeutics, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Experimental drug aims to curb brain bleeds in rare genetic disease Results expected Dec 2026 (estimated)
- Can a pill clear the toxic proteins behind Alzheimer's? Results expected Apr 2027 (estimated)
-
Can a pill clear the toxic proteins behind Alzheimer's?
Disease control OngoingThis trial tests an experimental drug called NPI-001 in people aged 50 to 85 with mild cognitive impairment or mild Alzheimer's disease. Participants take either the drug or a placebo as tablets twice daily for 12 months, with doses increasing over time. The study measures safety…
Phase 2 • Sponsor: Arctic Therapeutics • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Experimental drug aims to curb brain bleeds in rare genetic disease
Disease control OngoingThis study tests an experimental drug, NPI-001 (AT-001), in people with hereditary cystatin C amyloid angiopathy (HCCAA), a rare genetic condition that causes repeated brain bleeding and stroke. The trial includes about 15 participants aged 12 and older who carry the specific L68…
Phase 2 • Sponsor: Arctic Therapeutics • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC